Previous 10 | Next 10 |
Supply chain issues have led to materially weaker near-term results and guidance, and are likely playing a meaningful role in the recent deflation of Xylem's robust valuation multiples. Xylem management doesn't really have many good options for quickly resolving the electronic compone...
Danaher Schedules First Quarter 2022 Earnings Conference Call PR Newswire WASHINGTON , March 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2022 on Thursday, A...
Expanding initiative focused on next generation sequencing services helps to advance genomics research On the heels of Integrated DNA Technologies’ xGen™ NGS portfolio launch in December, MLL, the Munich Leukemia Laboratory , one of the leading research...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend Champion, Contender, An...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 11.8% and a median increase of 11.5%. I've tracked 190 increases in 2022. There are eight increases for next week, down from thirt...
After poor performance during 2015 to 2018, IXJ reshuffled its portfolio. Price return in the past 3 years is good and even better in the longer period. Price multiples suggest that IXJ is neither undervalued nor overvalued. For further details see: IXJ: A Healthcare ETF...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...
The stock market has been exhibiting immense volatility of late due to escalating economic sanctions on Russia in response to its invasion of Ukraine, inflationary pressures, and supply chain disruptions. However, some growth-focused companies should be able to capitalize on the steady econom...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...